Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Year: 2014
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Mitsune Tanimoto, Koichi Miyamura, Toshihiro Miyamoto, Kazuhito Yamamoto, Masafumi Taniwaki, Shinya Kimura, Kazuma Ohyashiki, Tatsuya Kawaguchi, Itaru Matsumura, Tomoko Hata, Hisashi Tsurumi, Shigeki Saito, Masayuki Hino, Seiji Tadokoro, Kuniaki Meguro, Hideo Hyodo, Masahide Yamamoto, Kohmei Kubo, Junichi Tsukada, Midori Kondo, Makoto Aoki, Hikaru Okada, Masamitsu Yanada
Institutions: Okayama University, Japanese Red Cross Nagoya Daiichi Hospital, Kyushu University Hospital, Aichi Cancer Center, Kyoto Prefectural University of Medicine, Saga University, Tokyo Medical University, Tokyo Medical University Hospital, Kumamoto University Hospital, Kindai University Hospital, Nagasaki University Hospital, Gifu University, Japanese Red Cross Nagoya Daini Hospital, Osaka City University, The University of Osaka, Sendai Medical Center, National Hospital Organization, Tokyo Medical and Dental University, Aomori Prefectural Central Hospital, University of Occupational and Environmental Health Japan, Novartis (Japan), Fujita Health University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2579468269